Search Results - "Patel, Anjan J"

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study by Cho, Byoung Chul, Abreu, Delvys Rodriguez, Hussein, Maen, Cobo, Manuel, Patel, Anjan J, Secen, Nevena, Lee, Ki Hyeong, Massuti, Bartomeu, Hiret, Sandrine, Yang, James Chih Hsin, Barlesi, Fabrice, Lee, Dae Ho, Ares, Luis Paz, Hsieh, Robert W, Patil, Namrata S, Twomey, Patrick, Yang, Xiaoying, Meng, Raymond, Johnson, Melissa L

“…Targeted inhibition of the PD-L1–PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory…”
Get full text

Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting by Khrystolubova, Natasha, Shieh, Monica, Patel, Anjan J, Bailey, Ray

“…Purpose To describe the outcomes of a pharmacist-led multi-center, collaborative patient education and proactive adverse event management program in a…”
Get full text

Outcomes of Surgery, Neoadjuvant Chemoradiation, or Definitive Chemoradiation for T2N0M0 Esophageal Adenocarcinomas from the National Cancer Data Base by Meredith, Kenneth L., MD, FACS, Shridhar, Ravi, MD, Huston, Jami, Patel, Anjan J., MD, Kucera, Steve, MD, Brown, Richard, MD, Lee, Justin S., MD

Get full text

Hemogram Derived Clinical Traits Evinced Differential Contribution to Explained Variance of Mortality Risk Model at Index Hospitalization for Sars-Cov-2 Infection across Wuhan/D614G, Delta, Omicron and Omicron BA.x Variants by Garcia, Gustavo, Hameed, Maha, Kayali, Zeina, Hamad, Karen, Wiese-Rometsch, Wilhelmine, Idogun, Precious, Patel, Anjan J.

“…Introduction SARS-CoV-2 infection promulgates an immune dysregulation that drives an inflammatory cascade therefore inducingmorbidity and mortality across the…”
Get full text

Complete Blood Count Parameters Outperform Putative Inflammatory Markers in Predicting COVID-19 Mortality: A Multimodal Machine Learning Model by Idogun, Precious, Sia, John, Ward, Mindy, Patel, Dillan, Wiese-Rometsch, Wilhelmine, Patel, Anjan J.

“…Introduction: SARS-CoV-2 evoked immunodysregulation drives inflammation, morbidity, and mortality across COVID-19 presentation spectrum. We sought to identify…”
Get full text

Systematic Literature Review and Meta-Analysis of Comparative Clinical Evidence Investigating Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line Treatment for Transplant-Ineligible Newly Diagnosed Multiple Myeloma by Gordan, Lucio, Medhekar, Rohan, Fu, Alex Z., Ramirez, Abril Oliva, Bonar, Nicolle, Nguyen, Bao-Ngoc, Spence, Michaela, McTavish, Rebecca, Disher, Tim, Kaila, Shuchita, Patel, Anjan J.

“…Background: Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are…”
Get full text

Use Of Fondaparinux For Venous Thromboembolism Prophylaxis In Critically Ill Adult Patients With Moderate Renal Insufficiency by Patel, Anjan J, Zumberg, Marc, Cope, Jessica, Bushwitz, Jennifer, Antigua, Abigail D

“…Fondaparinux, a selective activated Factor Xa inhibitor, is a parenteral anticoagulant primarily excreted by the kidneys. Renal insufficiency (RI), commonly…”
Get full text

Successful percutaneous coronary intervention in a patient with combined deficiency of FV and FVIII due to novel compound heterozygous mutations in LMAN1 by Patel, A. J., Liu, H.-H., Lager, R. A., Malkovska, V., Zhang, B.

“…Summary Percutaneous coronary intervention (PCI) in patients with congenital coagulation factor deficiencies presents a unique challenge. They are not only at…”
Get full text